RESUMO
The tablet form of amiodarone is indicated for the treatment of recurrent ventricular fibrillation or hemodynamically unstable ventricular tachycardia. It is recommended that the tablet be taken with meals in cases of gastrointestinal intolerance. However, the effect of food on its bioavailability is unknown. The primary objective of this study was to determine the effect of food on the bioavailability of amiodarone. This was a 2-period crossover study conducted in 30 healthy male subjects. Subjects were randomly assigned to 1 of 2 sequences in which the following 2 treatments were administered: (1) a single-dose of amiodarone (three 200-mg Cordarone tablets) after an overnight fast, and (2) the same dose immediately after a standard high-fat breakfast. Plasma concentrations of amiodarone and desethylamiodarone (DEA) were measured for 6 weeks after each dose. Food enhanced the extent of absorption, resulting in a peak concentration (Cmax) and area under the curve (AUCT) 3.8 and 2.4 times the respective values under fasting conditions. Food also significantly increased the rate of absorption, reducing the time (tmax) to Cmax from 7.1 to 4.5 hours. The effect of food on DEA levels was significant but less pronounced. An in vitro dissolution study confirmed a marked difference between amiodarone release under simulated fed and fasting conditions. Thus, food significantly enhances both the rate and extent of absorption of amiodarone, which is attributed partially to the effect of food on drug release from its formulation. Therefore, it is recommended that amiodarone tablets be taken consistently with meals.
Assuntos
Amiodarona/farmacocinética , Antiarrítmicos/farmacocinética , Alimentos , Adulto , Amiodarona/administração & dosagem , Análise de Variância , Antiarrítmicos/administração & dosagem , Área Sob a Curva , Disponibilidade Biológica , Cromatografia Líquida de Alta Pressão , Humanos , Masculino , ComprimidosRESUMO
The primary objective of this study was to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of tasosartan and atenolol administered alone and concomitantly under steady-state conditions in 17 patients ages 18 to 65 years diagnosed with stage 1 to 2 essential hypertension. After a 3- to 14-day qualification period, all patients received placebo tasosartan on days--1 through 5 and 25 through 34, atenolol alone (50 mg) on days 1 through 5, atenolol (50 mg) + tasosartan (50 mg) on days 6 through 19, and tasosartan (50 mg) alone on days 20 through 24. A PK and PD evaluation of atenolol alone was performed on study day 5. On study day 19, PK and PD of both tasosartan and atenolol were assessed. PK and PD evaluation for tasosartan alone was assessed on study day 24. The coadministration of atenolol + tasosartan did not affect the pharmacokinetics of tasosartan, its major metabolite (enoltasosartan), or atenolol when compared with tasosartan or atenolol administered separately. For area under the change in diastolic blood pressure curve, the reduction was significantly greater after tasosartan + atenolol compared with that after atenolol alone (336 +/- 85 and 190 +/- 71 mmHg.24 h; p < 0.05 for combination and atenolol alone, respectively; mean +/- SEM). Combination therapy also caused a maximal reduction in diastolic blood pressure that is significantly more than with monotherapy with atenolol (-27 +/- 2 mmHg and -20 +/- 2 mmHg, respectively, p < 0.05). The additive effects of tasosartan and atenolol in decreasing diastolic blood pressure may provide a rationale for combination antihypertensive therapy.
Assuntos
Antagonistas Adrenérgicos beta/farmacologia , Angiotensina II/metabolismo , Antagonistas de Receptores de Angiotensina , Atenolol/farmacologia , Hipertensão/metabolismo , Pirimidinas/farmacologia , Tetrazóis/farmacologia , Adolescente , Antagonistas Adrenérgicos beta/administração & dosagem , Antagonistas Adrenérgicos beta/farmacocinética , Adulto , Idoso , Atenolol/administração & dosagem , Atenolol/farmacocinética , Sinergismo Farmacológico , Humanos , Hipertensão/tratamento farmacológico , Pessoa de Meia-Idade , Pirimidinas/administração & dosagem , Pirimidinas/farmacocinética , Método Simples-Cego , Tetrazóis/administração & dosagem , Tetrazóis/farmacocinéticaRESUMO
BACKGROUND: There are large interindividual differences in CYP3A4 expression and in the metabolism of drug substrates for this enzyme. We and others have identified a polymorphism in the 5' promotor region of the CYP3A4 gene; however, its functional significance is not currently known. This study was conducted to determine whether this polymorphism plays a clinically important role in determining CYP3A4 phenotype. METHODS: An adenine (A) to guanine (G) transition was identified in the 5' promotor region of the CYP3A4 gene at position -292 (from the start codon), in a sequence motif known as the nifedipine-specific element. The frequency of this polymorphism was assessed in 802 healthy volunteers from five broadly defined racial groups. The population distribution of the G allele in these groups was as follows: white Americans (3.6%; n = 273), black Americans (54.6%, n = 186), Hispanic Americans (9.3%; n = 188), Japanese Americans (0.0%; n = 77), and Chinese Americans (0.0%; n = 78). In a subsequent study, 90 additional black Americans were genotyped, and a subset of the homozygous subjects (AA, n = 8; GG, n = 23) were given the CYP3A4 probe substrates erythromycin and nifedipine to allow genotype-phenotype comparisons to be made. RESULTS: There was no difference in the rate of CYP3A4-dependent demethylation of erythromycin (erythromycin breath test) or the pharmacokinetics of nifedipine or its CYP3A4-dependent metabolite dehydronifedipine between the two genotype groups (AA or GG). CONCLUSIONS: This promotor region polymorphism does not appear to play a major role in determining constitutive CYP3A4 expression.
Assuntos
Sistema Enzimático do Citocromo P-450/genética , Oxigenases de Função Mista/genética , Polimorfismo Genético , Regiões Promotoras Genéticas/genética , Grupos Raciais/genética , Área Sob a Curva , Povo Asiático/genética , População Negra/genética , Testes Respiratórios , Bloqueadores dos Canais de Cálcio/metabolismo , Citocromo P-450 CYP3A , Primers do DNA , Eritromicina/metabolismo , Genótipo , Hispânico ou Latino/genética , Humanos , Nifedipino/metabolismo , Fenótipo , Inibidores da Síntese de Proteínas/metabolismo , Valores de Referência , População Branca/genéticaRESUMO
REV 2871 (CHBZ) and its putative metabolite REV 3579-Z (also designated in the literature as RHC 3579-Z) were shown to be potent and orally effective inhibitors of passive cutaneous anaphylaxis (PCA) in the rat (ED50 = 12 mg/kg). The activity profiles of CHBZ, REV 3579-Z and disodium cromoglycate (DSCG) were compared as inhibitors of histamine release (HR) in vitro from rat mast cells, human basophils, and guinea pig lung slices. CHBZ was a potent inhibitor of both immunologic and non-immunologic HR (I50 2-20 microM from rat mast cells). The activity profile of CHBZ as an inhibitor of HR from rat mast cells differed from that of DSCG and REV 3579-Z in the following respects: increasing inhibition of HR with increasing preincubation time; irreversibility of the inhibition; lack of tachyphylaxis and cross-tachyphylaxis to DSCG; potentiation of the inhibition of antigen-induced release of histamine (AIR) by DSCG; and inhibition of HR induced by dextran + phosphatidyl serine, compound 48/80, ionophore A23187 and platelet activating factor (PAF). In the human basophil model, CHBZ was: a potent inhibitor (I50 = 25 microM) of anti-IgE-induced release (AbIR), whereas DSCG and REV 3579-Z had no effect on AbIR; more potent as an inhibitor of AbIR than ionophore-induced release, whereas the reverse was true for proxicromil; an inhibitor of PAF-induced release, whereas proximcromil stimulated it; and potentiative with proxicromil for inhibition of AbIR. In the guinea pig lung slice model, CHBZ inhibited AIR (I50 = 800 microM) whereas DSCG and REV 3579-Z did not (I50 greater than 300 microM). We conclude that CHBZ is an orally effective antiallergic agent whose mechanism of action as an inhibitor of mediator release is different from DSCG and proxicromil.
Assuntos
Antagonistas dos Receptores Histamínicos H1/farmacologia , Liberação de Histamina/efeitos dos fármacos , Oxazóis/farmacologia , Animais , Antígenos/imunologia , Basófilos/metabolismo , Calcimicina/farmacologia , Cromonas/farmacologia , Cromolina Sódica/farmacologia , Dextranos/farmacologia , Sinergismo Farmacológico , Cobaias , Humanos , Imunoglobulina E/imunologia , Técnicas In Vitro , Pulmão/metabolismo , Mastócitos/metabolismo , Fosfatidilserinas/farmacologia , Fator de Ativação de Plaquetas/farmacologia , Ratos , Taquifilaxia , Fatores de Tempo , p-Metoxi-N-metilfenetilamina/farmacologiaRESUMO
REV 2871 (CHBZ) was taken up by rat mast cells and human leukocytes in a specific and saturable manner. The compound can be hydrolyzed by a granule-associated enzyme in the mast cell to an ionic metabolite (REV 3579) whose in vitro profile is identical to that of disodium cromoglycate (DSCG). REV 3579, although achieving millimolar concentrations inside cells incubated with CHBZ, was not itself taken up by rat mast cells or human leukocytes. The unusual in vitro activity of CHBZ is postulated to arise from the fact that it is a prodrug for delivering a DSCG-like drug to the interior of a secretory cell. The internalized drug apparently exerts a more general and longer-lived inhibition of the secretory process than it can by acting on exterior membrane receptors. CHBZ thus represents a novel drug for studying anaphylactic responses in vitro.
Assuntos
Antagonistas dos Receptores Histamínicos H1/metabolismo , Oxazóis/metabolismo , Acilação , Animais , Ligação Competitiva , Cromolina Sódica/farmacologia , Humanos , Hidrólise , Técnicas In Vitro , Cinética , Leucócitos/metabolismo , Mastócitos/metabolismo , Oxazóis/farmacologia , Cavidade Peritoneal/citologia , RatosRESUMO
A series of new substituted arylmethyl phenyl ethers has been prepared. These compounds were tested as inhibitors of 5-lipoxygenase (5-LO) in rat neutrophils, in vitro antagonists of leukotriene-induced contraction of guinea pig (GP) lung parenchymal strips, and inhibitors of slow reacting substance of anaphylaxis (SRS-A) mediated bronchospasm in the GP in vivo. Most representatives of this new class of potential antiallergic/antiinflammatory agents showed potent inhibition of 5-LO activity in rat PMNs. The most potent compound, 2-[[3-(1-hydroxyhexyl)phenoxy]-methyl]quinoline (33), had an I50 of 0.12 microM in the rat PMN 5-LO assay and an I50 of 3.6 microM in the leukotriene-induced contraction of GP lung parenchymal strips, and it also showed 91% inhibition of SRS-A-mediated bronchospasm in the GP in vivo at 10 mg/kg, administered intraduodenally. Some of the compounds in this series were also leukotriene antagonists in vitro, and several of them showed in vivo activity against SRS-A-mediated bronchospasm in the GP.
Assuntos
Araquidonato Lipoxigenases/antagonistas & inibidores , Inibidores de Lipoxigenase , Éteres Fenílicos/síntese química , SRS-A/antagonistas & inibidores , Animais , Ácidos Hidroxieicosatetraenoicos/sangue , Indicadores e Reagentes , Pulmão/efeitos dos fármacos , Pulmão/fisiologia , Neutrófilos/efeitos dos fármacos , Neutrófilos/fisiologia , Éteres Fenílicos/farmacologia , Ratos , SRS-A/farmacologia , Relação Estrutura-AtividadeRESUMO
CHBZ is a novel, non-disodium cromoglycate (DSCG)-like, antiallergic drug in vitro. Whereas DSCG loses antisecretory activity with increasing time of preincubation with rat mast cells (RMC) before antigen challenge, and does not inhibit non-immunologically mediated release from human leukocytes, CHBZ exerts long-lived inhibition of both types of release from both types of cells. CHBZ is taken up by RMC in a saturable and time-dependent manner. It is enzymatically converted inside RMC to a DSCG-like metabolite, REV 3579, which, because of its ionic character, accumulates inside the cell. CHBZ, presumably through the action of the REV 3579 generated intracellularly, may mediate long-lived phosphorylation of the same 78 K protein which is transiently phosphorylated upon exposure of RMC to DSCG.
Assuntos
Antagonistas dos Receptores Histamínicos H1/farmacologia , Liberação de Histamina/efeitos dos fármacos , Oxazóis/farmacologia , Animais , Transporte Biológico , Radioisótopos de Carbono , Humanos , Imunoglobulina E/imunologia , Cinética , Leucócitos/efeitos dos fármacos , Leucócitos/imunologia , Mastócitos/efeitos dos fármacos , Mastócitos/imunologia , Oxazóis/metabolismo , Técnica de Diluição de Radioisótopos , Ratos , Ratos Endogâmicos , Relação Estrutura-AtividadeRESUMO
Celiprolol has been previously shown in vivo to be an effective beta-adrenergic antagonist with cardio-selectivity and weak intrinsic sympathomimetic activity but no membrane stabilizing or "quinidine-like" effects. With in vitro systems reported here, the following was observed. Against the stimulation of adenylate cyclase from dog ventricular muscle by isoproterenol, celiprolol had a Ki of 2.6 X 10(-7) M which was about 1/20 the potency of propranolol. At 100 microM, celiprolol did not affect histamine or dopamine concentration-response curves for the stimulation of adenylate cyclase from guinea-pig cerebral cortex. By itself, up to 1 mM, celiprolol did not affect basal adenylate cyclase activity from either preparation. With in vitro radioligand binding assays to directly measure beta-adrenergic receptor interactions, celiprolol had Ki values of 1.4 X 10(-7) to 8.3 X 10(-6) M. A 35-fold beta selectivity was noted with membranes from rat heart vs. rat reticulocytes, which supports previously reported in vivo data on cardioselectivity. No difference in affinity to beta-receptors was noted with frog vs. turkey erythrocyte membranes which supports the contention that these two non-mammalian systems are not predictive of beta1/beta2 specificity with mammalian systems. Celiprolol also showed some selective alpha2-adrenoceptor antagonism against (3H)-yohimbine binding vs. (3H)-prazosin binding to membranes from rat cerebral cortex. With rat adipocytes, up to 300 microM celiprolol did not stimulate basal lipolysis in the presence or absence of 10 microM 1-methyl-3-isobutyl-xanthine. Celiprolol inhibited isoproterenol-induced lipolysis with a potency about 2 times greater than practolol. Unlike propranolol, celiprolol at very high concentrations did not show non-specific inhibition of lipolysis induced with cyclic nucleotides. These and other published data would suggest the following: in vitro beta adrenergic receptor antagonist activity can be demonstrated for celiprolol, cardioselectivity is due to a combination of many factors including stereochemistry of the molecule and in vivo distribution and metabolism, celiprolol does not possess "non-specific" membrane activity, the "intrinsic-sympathomimetic activity" of celiprolol is selectively observed in some but not all in vitro test models, celiprolol has about a 10-fold selectivity for alpha 2-vs. alpha 1-receptors which is relatively unique to beta-antagonists and needs further investigations as to the potential physiological significance.
Assuntos
Adenilil Ciclases/metabolismo , Antagonistas Adrenérgicos beta/farmacologia , Lipólise/efeitos dos fármacos , Propanolaminas/farmacologia , Receptores Adrenérgicos alfa/metabolismo , Receptores Adrenérgicos beta/metabolismo , Tecido Adiposo/metabolismo , Animais , Anuros , Celiprolol , Córtex Cerebral/metabolismo , Cães , Cobaias , Técnicas In Vitro , Pulmão/metabolismo , Masculino , Membranas/metabolismo , Miocárdio/metabolismo , Prazosina/metabolismo , Ratos , Reticulócitos/metabolismo , Especificidade da Espécie , Perus , Ioimbina/metabolismoRESUMO
A comparison of the structure-activity relationships [SAR] for a number of compounds containing a dihydropyridine ring were investigated in vitro for the inhibition of [3H]-nitrendipine binding to membranes from rat ventricular muscle vs the inhibition of cyclic nucleotide phosphodiesterases [cNUC-PDE]. Although there were some gross similarities in the 2 SARs for these compounds, there were sufficient differences to indicate that these are 2 distinctly different biochemical properties of these compounds. Some of these compounds were relatively potent inhibitors of both cNUC-PDE and (3H)-nitrendipine binding. However, some analogs were potent inhibitors of one of the activities but relatively ineffective against the other activity. These data suggest that these 2 different biochemical mechanisms of action (and possibly others) may jointly influence the overall pharmacological profile of these compounds and indicate at least one reason why some of these compounds have different profiles of activity in vivo.
Assuntos
2',3'-Nucleotídeo Cíclico Fosfodiesterases/antagonistas & inibidores , Bloqueadores dos Canais de Cálcio/farmacologia , Di-Hidropiridinas , Nifedipino/análogos & derivados , Piridinas/farmacologia , Animais , Ligação Competitiva/efeitos dos fármacos , Técnicas In Vitro , Cinética , Masculino , Miocárdio/enzimologia , Nifedipino/metabolismo , Nitrendipino , Ratos , Relação Estrutura-AtividadeRESUMO
A series of 26 compounds belonging to the chemical class of (1,2,4)triazolo(4,3-a)-quinoxaline-1,4-diones have been investigated for their antiallergic activities in 3 in vitro models of anaphylaxis. Effects of these and other known antiallergic agents on cyclic nucleotide phosphodiesterases (cNUC-PDE) from purified rat mast cells have also been investigated. 18 compounds were potent (I50 less than or equal to 45 microM) inhibitors of antigen-induced release of histamine (AIR) from rat mast cells (RMC), 3 compounds inhibited anti-IgE-induced release of histamine from human basophils (I50 less than or equal to 25 microM) and none of the compounds significantly affected AIR from guinea pig lung slices. 13 of the compounds were more potent than theophylline as inhibitors of cyclic AMP-PDE and/or cyclic GMP-PDE from RMC. Parallel concentration-response curves for the inhibition of cyclic AMP-PDE and cyclic GMP-PDE indicated that these compounds probably interact with enzyme in the same manner. Paired regression analysis of the I50 values for inhibition of AIR and cNUC-PDE from RMC by these compounds revealed no statistically significant correlation between the inhibition of AIR and inhibition of cyclic AMP-PDE or cyclic GMP-PDE. We conclude: (1) some of these compounds are potent inhibitors of immunologic release of histamine from RMC with an in vitro activity profile similar to that of DSCG, and (2) inhibition of cyclic AMP or cyclic GMP hydrolysis by cNUD-PDE by these compounds, DSCG, and 6 known antiallergic agents is not the biochemical mechanism by which they inhibit AIR from RMC.
Assuntos
2',3'-Nucleotídeo Cíclico Fosfodiesterases/antagonistas & inibidores , Antagonistas dos Receptores Histamínicos H1/farmacologia , Liberação de Histamina/efeitos dos fármacos , Hipersensibilidade/tratamento farmacológico , Inibidores de Fosfodiesterase , Triazóis/farmacologia , 3',5'-AMP Cíclico Fosfodiesterases/antagonistas & inibidores , Animais , Anticorpos Anti-Idiotípicos/fisiologia , Antígenos/imunologia , Basófilos/imunologia , Cromolina Sódica/farmacologia , Depressão Química , Cobaias , Humanos , Imunoglobulina E/imunologia , Imunoglobulina E/fisiologia , Cinética , Pulmão/imunologia , Masculino , Mastócitos/imunologia , Ovalbumina/imunologia , Diester Fosfórico Hidrolases , Ratos , Ratos EndogâmicosRESUMO
RHC 3288 [1-methyl-2(1,3,4-oxadiazol-2(3H)-one-5-yl) benzimidazole] and twenty-five related 5-substituted oxadiazolones have been investigated for their antiallergic activities in three in vitro models of anaphylaxis. Sixteen compounds were potent (I50 less than or equal to 50 microM) inhibitors of antigen-induced release of histamine (AIR) from rat mast cells (RMC), and seven compounds inhibited anti-IgE-induced release of histamine from human basophils (I50 less than or equal to 100 microM). The antiallergic activity profiles of RHC 3288 and three other compounds in these models have been compared with that of disodium cromoglycate (DSCG). As inhibitors of AIR from RMC, RHC 3288, 3334, 3354 and 3380 were 3 to 10 times more potent than DSCG. In the same model (AIR from RMC), activity profiles of all four RHC compounds were identical to that of DSCG in the following respects: loss of inhibitory activity with increasing preincubation time, tachyphylaxis and cross-tachyphylaxis to each other, and inability to inhibit histamine release stimulated by Ca2+ ionophore, dextran + phosphatidyl serine and compound 48/80. RHC 3288, 3334, 3354 and DSCG had no effect in the other two models, histamine release from guinea pig lung mediated predominantly by IgG1 class of antibodies and anti-IgE-induced histamine release from human basophils. We conclude that RHC 3288 is a potent inhibitor of mediator release with a mechanism of action similar to that of DSCG.
Assuntos
Basófilos/metabolismo , Liberação de Histamina , Mastócitos/metabolismo , Oxidiazóis/farmacologia , Animais , Calcimicina/farmacologia , Cromolina Sódica/farmacologia , Dextranos/farmacologia , Interações Medicamentosas , Cobaias , Antagonistas dos Receptores Histamínicos/farmacologia , Humanos , Pulmão/metabolismo , Fosfatidilserinas/farmacologia , Ratos , Taquifilaxia , Fatores de TempoRESUMO
Nylidrin (RHC 3432-A) has been investigated for its antiallergic activity in three in vitro models. Nylidrin was an effective inhibitor of IgE-mediated release of histamine from passively sensitized rat peritoneal mast cells and human basophils, and of IgG1-mediated release of histamine from passively sensitized guinea pig lung slices. The inhibition of the release of histamine by nylidrin in all three models was not antagonized by propranolol, indicating that nylidrin does not inhibit histamine release via stimulation of beta-adrenergic receptors. Isoproterenol and epinephrine were effective as inhibitors of the release of histamine only from guinea pig lung while salbutamol and terbutaline had no effect on immunologic release of histamine in all three models. Detailed comparative studies with disodium cromoglycate (DSCG) indicated that the mechanism of action of nylidrin in the rat mast cell model is different from that of DSCG.
Assuntos
Basófilos/efeitos dos fármacos , Antagonistas dos Receptores Histamínicos H1 , Liberação de Histamina/efeitos dos fármacos , Pulmão/efeitos dos fármacos , Mastócitos/metabolismo , Nilidrina/farmacologia , Animais , Basófilos/metabolismo , Cromolina Sódica/farmacologia , Reações Cruzadas , Dextranos/farmacologia , Cobaias , Humanos , Pulmão/metabolismo , Mastócitos/imunologia , Fosfatidilserinas/farmacologia , Ratos , Fatores de TempoRESUMO
Nylidrin hydrochloride has weak beta-adrenergic agonist properties with rat mast cells, and shows synergy with 3-isobutyl-1-methylxanthine (IBMX) in raising intracellular cAMP in purified mast cells; both of these properties can be blocked by dl-propranolol. However, the action of nylidrin hydrochloride as an inhibitor of histamine secretion from purified rat mast cells is not antagonized by dl-propranolol, nor is it potentiated by IBMX. Nylidrin-induced elevation of cellular cAMP in purified rat mast cells shows no correlation with nylidrin-induced inhibition of histamine release. Thus, nylidrin hydrochloride inhibits release of histamine from mast cells by a novel, non-adrenergic mechanism, which is not dependent on increased levels of cAMP.
Assuntos
AMP Cíclico/análise , Antagonistas dos Receptores Histamínicos H1 , Liberação de Histamina , Mastócitos/análise , Nilidrina/farmacologia , Animais , Anticorpos Anti-Idiotípicos/farmacologia , Imunoglobulina E/imunologia , Inibidores de Fosfodiesterase/farmacologia , Propranolol/farmacologia , Ratos , Ratos EndogâmicosRESUMO
Tiaramide (RHC 2592-A) is an analgesic agent with antiallergic activity in vivo. We have investigated the antianaphylactic properties of tiaramide and its metabolites in three in vitro models of anaphylaxis; namely, IgE-induced release of histamine from rat mast cells and human basophils, and IgG1-induced release of histamine from guinea pig lung slices. Tiaramide and one of the metabolites, desethanol tiaramide (DETR), were found to inhibit immunologic release of histamine in all three of these in vitro models. Although tiaramide and DETR were less potent than disodium cromoglycate (DSCG) and/or proxicromil as inhibitors of mediator release, they were not cross-tachyphylactic to DSCG in the rat mast cell model. These data indicate that tiaramide is a unique inhibitor of histamine release whose mechanism of action differs from that of DSCG, and which in vivo is converted to a more potent metabolite.
Assuntos
Anti-Inflamatórios , Liberação de Histamina/efeitos dos fármacos , Piperazinas/farmacologia , Anafilaxia/tratamento farmacológico , Animais , Basófilos/efeitos dos fármacos , Benzotiazóis , Cromonas/farmacologia , Cromolina Sódica/farmacologia , Antagonistas dos Receptores Histamínicos H1/farmacologia , Hipersensibilidade/tratamento farmacológico , Técnicas In Vitro , Pulmão/efeitos dos fármacos , Mastócitos/efeitos dos fármacos , RatosRESUMO
The pharmacodynamic profile of bucainide dimaleate (RHC G-233) in dogs has been studied. The first observed pharmacologic effect was a change in the ECG pattern (T-wave duration and amplitude) that occurred after an average intravenous dose of 2.7 mg/kg. The average plasma concentration of bucainide was approximately 350 ng/ml. Analysis of data from dogs that received a dual infusion of bucainide indicated that bucainide has an extensive volume of distribution, with an average value of approximately 26 l/kg. An average terminal half-life of 89 minutes was observed. Studies with the radiolabeled drug in rats and dogs also demonstrated the drug's large volume of distribution, and its initial rapid disappearance from the blood. Tissue distribution studies in the rat after administration of the radiolabeled drug showed that bucainide is rapidly taken up by the tissues.